Latest Articles

Publication Date
All News Scientific
Luteinizing hormone profiles during ovarian stimulation in assisted reproductive treatment.

Few data is available on the natural course of luteinizing hormone (LH) during ovarian stimulation, but it has been suggested that 'oversuppressed' LH could decrease fertility outcomes. Our aim with …

Published: Dec. 4, 2024, midnight
Read Full Article
antagonist hormonal profile luteinizing hormone (LH) ovarian stimulation oversuppression
New research links depression to more painful periods - Fast Company

New research links depression to more painful periods Fast Company

Published: Dec. 3, 2024, 9:02 p.m.
Read Full Article
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn

Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn

Published: Dec. 3, 2024, 6:36 p.m.
Read Full Article
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive

Published: Dec. 3, 2024, 5:11 p.m.
Read Full Article
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News - StockTitan

Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News StockTitan

Published: Dec. 3, 2024, 1 p.m.
Read Full Article
Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News - StockTitan

Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News StockTitan

Published: Dec. 3, 2024, noon
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!